Investment
Features
FeesSafety
Academy
More
Pluang+

St. Louis Blues to air 10 Thursday games on Gray Media's ABC 32 in 2026-27 season

Market News
12 Oct 2026
Na
View Source
Bullish
St. Louis Blues to air 10 Thursday games on Gray Media's ABC 32 in 2026-27 season

The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million households across the Midwest, allowing fans to watch via antenna and other providers. The partnership also includes weekly shows and features on local news, enhancing fan engagement. The games will be simulcast with Blue Note+ production but without pre/postgame shows on ABC 32.

The St. Louis Blues Thursday Night Blues package announcement provides context for media sector trading on Pluang. For readers following the media sector, here is Pluang's market snapshot as of Oct 12, 2026 18:12 WIB: out of 51 priced US media stocks, 22 rose and 17 fell today. NFLX (Netflix Inc) and MANU (Manchester United PLC) both gained +0.68%, priced at USD 70.78 and USD 20.65 respectively, while TME (Tencent Music Entertainment Group - ADR) declined by -0.60% to USD 8.33. Typical hold times range from 68 days for TME to 126 days for NFLX.

More News

Harmony Biosciences appoints Peter Anastasiou as new CEO starting January 2027, with current CEO retiring.

Harmony Biosciences appoints Peter Anastasiou as new CEO starting January 2027, with current CEO retiring.

Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...

Company Fundamentals
Bullish
16 minutes ago
Obexelimab shows sustained benefits in IgG4-related disease, reducing steroid toxicity and supporting vaccine response.

Obexelimab shows sustained benefits in IgG4-related disease, reducing steroid toxicity and supporting vaccine response.

Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...

Market News
Bullish
16 minutes ago
Fate Therapeutics appoints Jamie Harrell to lead commercialization of CAR T-cell therapies for autoimmune diseases.

Fate Therapeutics appoints Jamie Harrell to lead commercialization of CAR T-cell therapies for autoimmune diseases.

Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...

Market News
Bullish
16 minutes ago
Study shows MicroPulse laser therapy cuts eye pressure and meds in glaucoma patients over 2 years

Study shows MicroPulse laser therapy cuts eye pressure and meds in glaucoma patients over 2 years

Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...

Market News
Bullish
16 minutes ago
EU selects Neo's Silmet 2.0 as strategic project, boosting Greenland Mines' rare earth supply role.

EU selects Neo's Silmet 2.0 as strategic project, boosting Greenland Mines' rare earth supply role.

The European Commission has chosen Neo Performance Materials' Silmet 2.0 as one of 46 Strategic Projects under the EU's Critical Raw Materials Act, recognizing its importance in rare earth processing. Greenland Mines, a key shareholder in Neo, sees t...

Market News
Bullish
16 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App